InMed Pharmaceuticals Inc 8-K, filed Dec 20, 2021
InMed Pharmaceuticals Inc. (MTRI)
About this 8-K
InMed Pharmaceuticals Inc filed this 8-K on December 20, 2021, reporting on events of December 17, 2021.
Items reported
- Item 5.07: Shareholder vote results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
(Date of Report - date of earliest event reported)
(Exact Name of Registrant as Specified in Its Charter)
|
(State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
|
| |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant's Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.07: Submission of Matters to a Vote of Security Holders
On December 17, 2021, InMed Pharmaceuticals Inc., or the “Corporation”, held its Annual General Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:
Proposal No. 1—Election of Directors
The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2022 Annual General Meeting:
| Nominee | Votes For | % Votes For | Votes Withheld | %Votes Withheld | Broker Non-Votes | |||||||||||||||
| Eric A. Adams | 2,960,270 | 93.98 | 189,717 | 6.02 | 2,821,286 | |||||||||||||||
| Adam Cutler | 2,980,880 | 94.63 | 169,107 | 5.37 | 2,821,286 | |||||||||||||||
| William J. Garner | 2,957,803 | 93.90 | 192,184 | 6.10 | 2,821,286 | |||||||||||||||
| Andrew Hull | 2,980,096 | 94.61 | 169,891 | 5.39 | 2,821,286 | |||||||||||||||
| Catherine Sazdanoff | 2,902,565 | 92.14 | 247,422 | 7.86 | 2,821,286 | |||||||||||||||
Proposal No. 2—Appointment of Independent Registered Public Accounting Firm
The Corporation’s shareholders voted to approve the appointment of KPMG LLP as the independent registered public accounting firm of the Corporation until the next annual shareholders’ meeting or until a successor is named.
| Votes For | % Votes For | Vote Against | % Votes Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 5,787,855 | 96.93 | 0 | 0.00 | 183,418 | 0 | |||||||||||||||||
Item 9.01 Exhibits.
(d) Exhibits.
| Exhibit 99.1. | News release, dated December 17, 2021 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 17, 2021
| INMED PHARMACEUTICALS INC. | ||
| By: | /s/ Bruce Colwill | |
| Name: | Bruce Colwill | |
| Title: | Chief Financial Officer | |
2
Exhibit 99.1
|
NASDAQ: INM
Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com |
InMed Announces Results of 2021 Annual General Meeting
Vancouver, BC – December 17, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today confirmed that, at its annual general meeting of shareholders held on December 17, 2021 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 28, 2021, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:
| Votes For | Withheld Votes | |||||||||||||||
| Director | Number | Percentage | Number | Percentage | ||||||||||||
| Eric A. Adams | 2,960,270 | 93.98 | % | 189,717 | 6.02 | % | ||||||||||
| Adam Cutler | 2,980,880 | 94.63 | % | 169,107 | 5.37 | % | ||||||||||
| William J. Garner | 2,957,803 | 93.90 | % | 192,184 | 6.10 | % | ||||||||||
| Andrew Hull | 2,980,096 | 94.61 | % | 169,891 | 5.39 | % | ||||||||||
| Catherine Sazdanoff | 2,902,565 | 92.14 | % | 247,422 | 7.86 | % | ||||||||||
InMed filed a report of voting results on SEDAR at www.sedar.com on December 17, 2021.
About InMed: InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com and www.baymedica.com.
Investor Contact:
Colin Clancy
Senior Director, Investor Relations
T: +1 604 416 0999
E: cclancy@inmedpharma.com
Edison Group:
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
E: jgreen@edisongroup.com / lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about; being a global leader in the manufacturing and development of rare cannabinoids and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.